Welcome to Decoding Bio’s BioByte: each week our writing collective highlight notable news—from the latest scientific papers to the latest funding rounds—and everything in between.
Parallel Bio could be a new arrow in the quiver for testing immunogenicity of drug candidates.
Parallel Bio could be a new arrow in the quiver for testing immunogenicity of drug candidates.